Related Experiment Videos
Tumor-cell targeted epiderimal growth factor liposomes loaded with boronated acridine: uptake and processing
Erika Bohl Kullberg1, Marika Nestor, Lars Gedda
1Division of Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, S-751 85 Uppsala, Sweden. Erika.Bohl@bms.uu.se
Pharmaceutical Research
|March 15, 2003
Summary
Targeted liposomes carrying boronated acridine showed specific cellular uptake and long retention in tumor cells, indicating potential for boron neutron capture therapy.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Liposomes are versatile nanocarriers for drug delivery.
- Polyethylene glycol (PEG)ylation enhances liposome stability and circulation time.
- Epidermal Growth Factor (EGF) is a potent mitogen involved in cell growth and proliferation.
Purpose of the Study:
- To investigate the cellular binding and processing of PEG-stabilized EGF-liposomes loaded with water-soluble boronated acridine (WSA).
- To evaluate the potential of these targeted liposomes for Boron Neutron Capture Therapy (BNCT).
Main Methods:
- Cellular uptake, internalization, and retention studies were performed on A-431 and U-343 cell lines.
- Subcellular localization of WSA was analyzed using confocal microscopy.
- The study considered the impact of the targeting agent (EGF), carrier (liposome), and payload (WSA).
Main Results:
- EGF-liposomes were internalized via specific binding to the EGF receptor.
- After internalization, WSA localized primarily in the cytoplasm of tumor cells.
- A high cellular retention of boron was observed, with 80% remaining after 48 hours.
Conclusions:
- The targeted liposomes demonstrated effective cellular uptake and prolonged retention of WSA.
- The achieved cellular boron concentrations suggest promising applications for BNCT.
- These findings support further development of EGF-liposomes for targeted cancer therapy.